Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Clasificación en acciones #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Precio por acción
$28.53
Capitalización bursátil
$1.96B
Cambio (1 día)
-1.65%
Cambio (1 año)
109.32%
País
IE
Comercio GH Research PLC (GHRS)

Categoría

Historial del precio de la acción de GH Research PLC (GHRS)
Precio más alto de cierre: $29.28 el 2026-08-01

Precio más bajo de cierre: $20.43 el 2021-06-01
Historial del precio de la acción de GH Research PLC desde 2021 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) 34.65%
2025 71.80%
2024 35.29%
2023 -44.18%
2022 -56.09%
2021 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$548.36 39.87%
US
$1.06K 50.29%
NL
$122.63 -11.69%
AU
$140.81 475.44%
US
$765.25 7.74%
CH